CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 20, 2008

Primary Completion Date

May 2, 2012

Study Completion Date

April 11, 2014

Conditions
HIV Infections
Interventions
DRUG

Maraviroc

Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)

Trial Locations (3)

90033

University Southern California, Los Angeles

90502

Harbor-UCLA, Torrance

92103

University California San Diego, San Diego

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

collaborator

University of Southern California

OTHER

collaborator

Pfizer

INDUSTRY

collaborator

California HIV/AIDS Research Program

OTHER

lead

University of California, San Diego

OTHER

NCT00925756 - CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery | Biotech Hunter | Biotech Hunter